Molecular links between COPD and lung cancer: new targets for drug discovery?

References

• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–2128.
   PubMed Web of Science ®Google Scholar
• Punturieri A, Szabo E, Croxton TL, et al. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst. 2009;101(8):554–559.
   PubMedGoogle Scholar
• Butler SJ, Ellerton L, Goldstein RS, et al. Prevalence of lung cancer in chronic obstructive pulmonary disease: A systematic review. Res Med. 2019. [Epub ahead of print]. DOI:10.1016/j.yrmex.2019.100003.
   Google Scholar
• Yang P, Sun Z, Krowka MJ, et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med. 2008;168(10):1097–1103.
   PubMedGoogle Scholar
• Carr LL, Jacobson S, Lynch DA, et al. Features of COPD as predictors of lung cancer. Chest. 2018;153(6):1326–1335.
   PubMed Web of Science ®Google Scholar
• Wang W, Mengshuang X, Shuang D, et al. The link between chronic obstructive pulmonary disease phenotypes and histological subtypes of lung cancer: a case-control study. Int J Chron Obstruct Pulmon Dis. 2018;13:1167–1175.
   PubMed Web of Science ®Google Scholar
• Turner MC, Chen Y, Krewski D, et al. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med. 2007;176(3):285–290.
   PubMed Web of Science ®Google Scholar
• Lusk CM, Wenzlaff AS, Watza D, et al. Quantitative imaging markers of lung function in a smoking population distinguish COPD sub-groups with differential lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2019;28(4):724–730.
   PubMed Web of Science ®Google Scholar
• Sanchez-Salcedo P, Wilson DO, de-Torres JP, et al. Improving selection criteria for lung cancer screening. The potential role of emphysema. Am J Respir Crit Care Med. 2015;191(8):924–931.
   PubMed Web of Science ®Google Scholar
• de-Torres JP, Sanchez-Salcedo P, Bastarrika G, et al. Telomere length, COPD and emphysema as risk factors for lung cancer. Eur Respir J. 2017;49(1):pii: 1601521.
   PubMed Web of Science ®Google Scholar
• Zamarrón E, Prats E, Tejero E, et al. Static lung hyperinflation is an independent risk factor for lung cancer in patients with chronic obstructive pulmonary disease. Lung Cancer. 2019;128:40–46.
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Skeans MA, Wise RA, et al. Lung health study research group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142(4):233–239.
   PubMed Web of Science ®Google Scholar
• Yao H, Rahman I. Current concepts on the role of inflammation in COPD and lung cancer. Curr Opin Pharmacol. 2009;9(4):375–383.
   PubMed Web of Science ®Google Scholar
• Papi A, Casoni G, Caramori G, et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small-cell lung cancer. Thorax. 2004;59(8):679–681.
   PubMed Web of Science ®Google Scholar
• Huang R, Wei Y, Hung RJ, et al. Associated links among smoking, chronic obstructive pulmonary disease, and small cell lung cancer: a pooled analysis in the international lung cancer consortium. EBioMedicine. 2015;2(11):1677–1685.
   PubMed Web of Science ®Google Scholar
• Conickx G, Mestdagh P, Avila Cobos F, et al. MicroRNA profiling reveals a role for microRNA-218-5p in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(1):43–56.
   PubMed Web of Science ®Google Scholar
• Eapen MS, Hansbro PM, McAlinden K, et al. Abnormal M1/M2 macrophage phenotype profles in the small airway wall and lumen in smokers and chronic obstructive pulmonary disease (COPD). Sci Rep. 2017;7(1):13392.
   PubMedGoogle Scholar
• Tang FS, Hansbro PM, Burgess JK, et al. A novel immunomodulatory function of neutrophils on rhinovirus-activated monocytes in vitro. Thorax. 2016;71(11):1039–1049.
   PubMed Web of Science ®Google Scholar
• Moheimani F, Roth H, Cross J, et al. β-Catenin/CBP complex disruption inhibits human airway epithelial-mesenchymal transition and repair. Int J Biochem Cell Biol. 2015;68:59–69.
   PubMed Web of Science ®Google Scholar
• Kedzierski L, Tate MD, Hsu AC, et al. Suppressor of cytokine signaling (SOCS)5 amerliorates influenza virus infection via inhibition of EGFR-PI3K signaling. eLife. 2017;6:e20444.
   PubMed Web of Science ®Google Scholar
• Fricker M, Goggins BJ, Mateer S, et al. Chronic smoke exposure induces systemic hypoxia that drives intestinal dysfunction. JCI Insight. 2018;3(3):pii94040.
   Web of Science ®Google Scholar
• Tolosa JM, Parsons KS, Hansbro PM, et al. The placental protein syncytin-1 impairs antiviral responses and exaggerates inflammatory responses to influenza. PLoS One. 2015;10(4):e0118629.
   PubMed Web of Science ®Google Scholar
• Hansbro PM, Hamilton MJ, Fricker M, et al. Importance of mast cell Prss31/transmembrane tryptase/tryptase-γ in lung function and experimental chronic obstructive pulmonary disease and colitis. J Biol Chem. 2014;289(26):18214–18227.
   PubMed Web of Science ®Google Scholar
• Hsu AC, Starkey MR, Hanish I, et al. Targeting PI3K-p110α suppresses influenza virus infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(9):1012–1023.
   PubMed Web of Science ®Google Scholar
• Jones B, Donovan C, Liu G, et al. Animal models of COPD: what do they tell us? Respirology. 2017;22(1):21–32.
   PubMed Web of Science ®Google Scholar
• Beckett EL, Stevens RL, Jarnicki AG, et al. A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis. J Allergy Clin Immunol. 2013;131(3):752–762.
   PubMed Web of Science ®Google Scholar
• Franklin BS, Bossaller L, De Nardo D, et al. The adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation. Nat Immunol. 2014;15(8):727–737.
   PubMed Web of Science ®Google Scholar
• Haw TJ, Starkey MR, Nair PM, et al. A pathogenic role for tumor necrosis factor-related apoptosis-inducing ligand in chronic obstructive pulmonary disease. Mucosal Immunol. 2016;9(4):859–872.
   PubMed Web of Science ®Google Scholar
• Tay HL, Kaiko GE, Plank M, et al. Antagonism of miR-328 increases the antimicrobial function of macrophages and neutrophils and rapid clearance of non-typeable Haemophilus Influenzae (NTHi) from infected lung. PLoS Pathog. 2015;11(4):e1004549.
   PubMed Web of Science ®Google Scholar
• Bazett M, Biala A, Huff RD, et al. Attenuating TH1-skewed immune pathology using a microbial-based intervention in a mouse model of cigarette smoke-induced lung inflammation. Respir Res. 2017;18(1):92.
   PubMedGoogle Scholar
• Haw TJ, Starkey MR, Pavlidis S, et al. Toll-like receptor 2 and 4 have opposing roles in the pathogenesis of cigarette smoke-induced chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2018;314(2):L298–L317.
   PubMed Web of Science ®Google Scholar
• Kameyama N, Chubachi S, Hegab AE, et al. Intermittent exposure to cigarette smoke increases lung tumors and the severity of emphysema more than continuous exposure. Am J Respir Cell Mol Biol. 2018;59(2):179–188.
   PubMed Web of Science ®Google Scholar
• Moghaddam SJ, Li H, Cho SN, et al. Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol. 2009;40(4):443–453.
   PubMed Web of Science ®Google Scholar
• Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452(7187):633–637.
   PubMed Web of Science ®Google Scholar
• Liu P, Vikis HG, Wang D, et al. Familiar aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst. 2008;100(18):1326–1330.
   PubMedGoogle Scholar
• Liu Y, Kheradmand F, Davis CF, et al. Focused analysis of exome sequencing data for rare germline mutations in familial and sporadic lung cancer. J Thorac Oncol. 2016;11(1):52–61.
   PubMed Web of Science ®Google Scholar
• Yang L, Qiu F, Lu X, et al. Functional polymorphisms of CHRNA3 predict risks of chronic obstructive pulmonary disease and lung cancer in Chinese. PLoS One. 2012;7(10):e46071.
   PubMed Web of Science ®Google Scholar
• Wu C, Hu Z, Yu D, et al. Genetic variants on chromosome 15q25 associated with lung cancer risk in Chinese populations. Cancer Res. 2009;69(12):5065–5072.
   PubMed Web of Science ®Google Scholar
• Pérez-Morales R, González-Zamora A, González-Delgado MF, et al. CHRNA3 rs1051730 and CHRNA5 rs16969968 polymorphisms are associated with heavy smoking, lung cancer, and chronic obstructive pulmonary disease in a mexican population. Ann Hum Genet. 2018;82(6):415–424.
   PubMed Web of Science ®Google Scholar
• Spitz MR, Amos CI, Dong Q, et al. The CHRNA5-A3 region on chromosome 15q24-25.1 is a risk factor both for nicotine dependence and for lung cancer. J Natl Cancer Inst. 2008;100(21):1552–1556.
   PubMedGoogle Scholar
• Lips EH, Gaborieau V, McKay JD, et al. Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000 individuals. Int J Epidemiol. 2010;39(2):563–577.
   PubMed Web of Science ®Google Scholar
• Racke K, Matthiesen S. The airway cholinergic system: physiology and pharmacology. Pulm Pharmacol Ther. 2004;17(4):181–198.
   PubMed Web of Science ®Google Scholar
• Song P, Sekhon HS, Proskocil B, et al. Synthesis of acetylcholine by lung cancer. Life Sci. 2003;72(18–19):2159–2168.
   PubMed Web of Science ®Google Scholar
• Pieper MP, Chaudhary NI, Park JE. Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide. Life Sci. 2007;80(24–25):2270–2273.
   PubMed Web of Science ®Google Scholar
• West KA, Brognard J, Clark AS, et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest. 2003;111(1):81–90.
   PubMed Web of Science ®Google Scholar
• Martínez-Moreno P, Nieto-Cerón S, Torres-Lanzas J, et al. Cholinesterase activity of human lung tumours varies according to their histological classification. Carcinogenesis. 2006;27(3):429–436.
   PubMed Web of Science ®Google Scholar
• Lam DC, Girard L, Ramirez R, et al. Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res. 2007;67(10):4638–4647.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Tang X, Zhang ZF, et al. Nicotine induces hypoxia-inducible factor-1alpha expression in human lung cancer cells via nicotinic acetylcholine receptor-mediated signaling pathways. Clin Cancer Res. 2007;13(16):4686–4694.
   PubMed Web of Science ®Google Scholar
• Carlisle DL, Liu X, Hopkins TM, et al. Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells. Pulm Pharmacol Ther. 2007;20(6):629–641.
   PubMed Web of Science ®Google Scholar
• Harknes LM, Kanabar V, Sharma HS, et al. Pulmonary vascular changes in asthma and COPD. Pulm Pharmacol Ther. 2014;29(2):144–155.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Last update 2019. goldcopd.org (accessibility verified on 1st of April 2019)
   Google Scholar
• Hrdlickova R, Toloue M, Tian B. RNA-Seq methods for transcriptome analysis. Wiley Interdiscip Rev RNA. 2017;8(1):e1364.
   PubMed Web of Science ®Google Scholar
• Zhou C, Chen H, Han L, et al. Screening of genes related to lung cancer caused by smoking with RNA-Seq. Eur Rev Med Pharmacol Sci. 2014;18(1):117–125.
   PubMed Web of Science ®Google Scholar
• Yeo J, Morales DA, Chen T, et al. RNAseq analysis of bronchial epithelial cells to identify COPD-associated genes and SNPs. BMC Pulm Med. 2018;18(1):42.
   PubMedGoogle Scholar
• Chang WA, Tsai MJ, Jian SF, et al. Systematic analysis of transcriptomic profiles of COPD airway epithelium using next-generation sequencing and bioinformatics. Int J Chron Obstruct Pulmon Dis. 2018;13:2387–2398.
   PubMed Web of Science ®Google Scholar
• Sandri BJ, Masvidal L, Murie C, et al. Distinct cancer-promoting stromal gene expression depending on lung function. Am J Respir Crit Care Med. 2019. [Epub ahead of print]. DOI:10.1164/rccm.201801-0080OC.
   PubMed Web of Science ®Google Scholar
• Ng Kee Kwong F, Nicholson AG, Pavlidis S, et al. PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD). BMC Cancer. 2018;18(1):1238.
   PubMedGoogle Scholar
• Anderson GP, Bozinovski S. Acquired somatic mutations in the molecular pathogenesis of COPD. Trends Pharmacol Sci. 2003;24(2):71–76.
   PubMed Web of Science ®Google Scholar
• Tuder RM, Yun JH, Graham BB. Cigarette smoke triggers code red: p21CIP1/WAF1/SDI1 switches on danger responses in the lung. Am J Respir Cell Mol Biol. 2008;39(1):1–6.
   PubMed Web of Science ®Google Scholar
• Sears CR. DNA repair ad an emerging target for COPD-lung cancer overlap. Respir Investig. 2019;57(2):111–121.
   PubMed Web of Science ®Google Scholar
• Popanda O, Edler L, Waas P, et al. Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer. 2007;55(1):25–34.
   PubMed Web of Science ®Google Scholar
• Lee YL, Chen W, Tsai WK, et al. Polymorphisms of p53 and p21 genes in chronic obstructive pulmonary disease. J Lab Clin Med. 2006;147(5):228–233.
   PubMed Web of Science ®Google Scholar
• Tomita K, Caramori G, Lim S, et al. Increased p21CIP1/WAF1 and bcl-xL expression and reduced apoptosis in alveolar macrophages from smokers. Am J Respir Crit Care Med. 2002;166(5):724–731.
   PubMed Web of Science ®Google Scholar
• Yao H, Yang SR, Edirisinghe I, et al. Disruption of p21 attenuates lung inflammation induced by cigarette smoke, LPS, and fMLP in mice. Am J Respir Cell Mol Biol. 2008;39(1):7–18.
   PubMed Web of Science ®Google Scholar
• Martín-Caballero J, Flores JM, García-Palencia P, et al. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res. 2001;61(16):6234–6238.
   PubMed Web of Science ®Google Scholar
• Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med. 2006;174(4):886–893.
   PubMedGoogle Scholar
• Russo AL, Thiagalingam A, Pan H, et al. Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin Cancer Res. 2005;11(7):2466–2470.
   PubMed Web of Science ®Google Scholar
• Marees T, Moll AC, Imhof SM, et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst. 2008;100(24):1771–1779.
   PubMedGoogle Scholar
• Ocak S, Sos ML, Thomas RK, et al. High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. Eur Respir J. 2009;34:489–506.
   PubMed Web of Science ®Google Scholar
• Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol. 2009;41(1):87–95.
   PubMed Web of Science ®Google Scholar
• Dubey S, Powell CA. Update in lung cancer 2008. Am J Respir Crit Care Med. 2009;179(10):860–868.
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148–1159.
   PubMed Web of Science ®Google Scholar
• Duruisseaux M, Esteller M. Lung cancer epigenetics: from knowledge to applications. Semin Cancer Biol. 2018;51:116–128.
   PubMed Web of Science ®Google Scholar
• Ji H, Ehrlich LI, Seita J, et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature. 2010;467(7313):338–342.
   PubMed Web of Science ®Google Scholar
• Selamat SA, Chung BS, Girard L, et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 2012;22(7):1197–1211.
   PubMed Web of Science ®Google Scholar
• Qiu W, Baccarelli A, Carey VJ, et al. Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. Am J Respir Crit Care Med. 2012;185(4):373–381.
   PubMed Web of Science ®Google Scholar
• Altenberger C, Heller G, Ziegler B, et al. SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers. Mol Cancer. 2017;16(1):1.
   PubMedGoogle Scholar
• Rauch TA, Zhong X, Wu X, et al. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci U S A. 2008;105(1):252–257.
   PubMed Web of Science ®Google Scholar
• Bojesen SE, Timpson N, Relton C, et al. AHRR (cg05575921) hypomethylation marks smoking behaviour, morbidity and mortality. Thorax. 2017;72(2):646–653.
   PubMedGoogle Scholar
• Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA. 1998;95(20):11891–11896.
   PubMed Web of Science ®Google Scholar
• Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000;60(1):5954–5958.
   PubMedGoogle Scholar
• Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008;358(11):1118–1128.
   PubMed Web of Science ®Google Scholar
• Wauters E, Janssens W, Vansteenkiste J, et al. DNA methylation profiling of non-small cell lung cancer reveals a COPD-driven immune-related signature. Thorax. 2015;70(12):1113–1122.
   PubMedGoogle Scholar
• Xie Q, Wu TP, Gimple RC, et al. N6-methyladenine DNA modification in Glioblastoma. Cell. 2018;175(5):1228–1243.
   PubMed Web of Science ®Google Scholar
• Moheimani F, Koops J, Williams T, et al. Influenza A virus infection dysregulates the expression of microRNA-22 and its targets; CD147 and HDAC4, in epithelium of asthmatics. Respir Res. 2018;19(1):145.
   PubMedGoogle Scholar
• Sohal SS, Hansbro PM, Walters EH. Epithelial mesenchymal transition in chronic obstructive pulmonary disease, a precursor for epithelial cancers: understanding and translation to early therapy. Ann Am Thorac Soc. 2017;14(9):1491–1492.
   PubMed Web of Science ®Google Scholar
• Nieto MA, Huang RY, Jackson RA, et al. EMT. Cell. 2016;166(1):21–45.
   PubMed Web of Science ®Google Scholar
• Shi L, Dong N, Fang X, et al. Regulatory mechanisms of TGF-β1-induced fibrogenesis of human alveolar epithelial cells. J Cell Mol Med. 2016;20(11):2183–2193.
   PubMed Web of Science ®Google Scholar
• David CJ, Huang YH, Chen M, et al. TGF-β tumor suppression through a lethal EMT. Cell. 2016;164(5):1015–1030.
   PubMed Web of Science ®Google Scholar
• Jiang B, Guan Y, Shen H, et al. Akt/PKB signaling regulates cigarette smoke-induced pulmonary epithelial-mesenchymal transition. Lung Cancer. 2018;122:44–53.
   PubMed Web of Science ®Google Scholar
• Rutting S, Xenaki D, Lau E, et al. Dietary omega-6, but not omega-3 polyunsaturated or saturated fatty acids, increase inflammation in primary lung mesenchymal cells. Am J Physiol Lung Cell Mol Physiol. 2018;314(2):L922–L935.
   PubMedGoogle Scholar
• Jiang G, Liu CT, Zhang WD, et al. IL-17A and GDF15 are able to induce epithelial-mesenchymal transition of lung epithelial cells in response to cigarette smoke. Exp Ther Med. 2018;16(1):12–20.
   PubMed Web of Science ®Google Scholar
• Shacter E, Weitzmann SA. Chronic inflammation and cancer. Oncology (Williston Park). 2002;16(2):217–26,229.
   PubMed Web of Science ®Google Scholar
• Lee JM, Yanagawa J, Peebles KA, et al. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol. 2008;66(3):208–217.
   PubMed Web of Science ®Google Scholar
• Reiman JM, Kmieciak M, Manjili MH, et al. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol. 2007;17(4):275–287.
   PubMed Web of Science ®Google Scholar
• Gong L, Da Silva Caetano M, Cumpian AM, et al. Tumor necrosis factor links chronic obstructive pulmonary disease and K-ras mutant lung cancer through induction of an immunosuppressive pro-tumor microenvironment. Oncoimmunology. 2016;5(10):e1229724.
   PubMed Web of Science ®Google Scholar
• Mateu-Jimenez M, Curull V, Pijuan L, et al. Systemic and tumor Th1 and Th2 inflammatory profile and macrophages in lung cancer: influence of underlying chronic respiratory disease. J Thorac Oncol. 2017;12(2):235–248.
   PubMed Web of Science ®Google Scholar
• Almatroodi SA, McDonald CF, Darby IA, et al. Characterization of M1/M2 tumour-associated macrophages (TAMs) and Th1/Th2 cytokine profles in patients with NSCLC. Cancer Microenviron. 2016;9(1):1–11.
   PubMed Web of Science ®Google Scholar
• Kerdidani D, Magkouta S, Chouvardas P, et al. Cigarette smoke-induced emphysema exhausts early cytotoxic CD8+ T cell responses against nascent lung cancer cells. J Immunol. 2018;201(5):1558–1569.
   PubMed Web of Science ®Google Scholar
• Murakami J, Ueda K, Sano F, et al. Pulmonary emphysema and tumor microenvironment in primary lung cancer. J Surg Res. 2016;200(2):690–697.
   PubMed Web of Science ®Google Scholar
• Lin Q, Guo L, Lin G, et al. Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer. Cancer Epidemiol. 2015;39(4):539–544.
   PubMed Web of Science ®Google Scholar
• Petta V, Loukides S, Kostikas K, et al. Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference? J Thorac Dis. 2018;10(10):740–748.
   PubMedGoogle Scholar
• Durham AL, Adcock IM. The relationship between COPD and lung cancer. Lung Cancer. 2015;90(2):121–127.
   PubMed Web of Science ®Google Scholar
• Ng Kee Kwong F, Nicholson AG, Harrison CL, et al. Is mitochondrial dysfunction a driving mechanism linking COPD to nonsmall cell lung carcinoma? Eur Respir Rev. 2017;26(146):pii:170040.
   PubMed Web of Science ®Google Scholar
• Bernardo I, Bozinovski S, Vlahos R. Targeting oxidant-dependent mechanisms for the treatment of COPD and its comorbidities. Pharmacol Ther. 2015;155:60–79.
   PubMed Web of Science ®Google Scholar
• Vlahopoulos S, Adamaki M, Khoury N, et al. Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer. Pharmacol Ther. 2019;194:59–72.
   PubMed Web of Science ®Google Scholar
• Miar A, Hevia D, Munoz-Cimadevilla H, et al. Manganese superoxide dismutase (SOD2/MnSOD)/catalase and SOD2/GPx1 ratios as biomarkers for tumor progression and metastasis in prostate, colon, and lung cancer. Free Radic Biol Med. 2015;85:45–55.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Senescence in COPD and its comorbidities. Annu Rev Physiol. 2017;79:517–539.
   PubMed Web of Science ®Google Scholar
• Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell. 2012;48(2):158–167.
   PubMed Web of Science ®Google Scholar
• Boelens MC, Gustafson AM, Postma DS, et al. A chronic obstructive pulmonary disease related signature in squamous cell lung cancer. Lung Cancer. 2011;72(2):177–183.
   PubMed Web of Science ®Google Scholar
• Peng H, Yang M, Chen ZY, et al. Expression and methylation of mitochondrial transcription factor a in chronic obstructive pulmonary disease patients with lung cancer. PLoS One. 2013;8(12):e82739.
   PubMed Web of Science ®Google Scholar
• Ping W, Jiang WY, Chen WS, et al. Expression and significance of hypoxia inducible factor-1α and lysyl oxidase in non-small cell lung cancer. Asian Pac J Cancer Prev. 2013;14(6):3613–3618.
   PubMedGoogle Scholar
• Chang SH, Mirabolfathinejad SG, Katta H, et al. T helper 17 cells play a critical pathogenic role in lungcancer. Proc Natl Acad Sci. 2014;111(15):5664–5669.
   PubMed Web of Science ®Google Scholar
• Jungnickel C, Schmidt LH, Bittigkoffer L, et al. Cigarette smoke-induced disruption of pulmonary barrier and bacterial translocation drive tumor-associated inflammation and growth. Am J Physiol Lung Cell Mol Physiol. 2015;309:605–613.
   Web of Science ®Google Scholar
• Simpson JL, Baines KJ, Horvat JC, et al. COPD is characterized by increased detection of haemophilus influenzae, streptococcus pneumoniae and a deficiency of bacillus species. Respirology. 2016;21(4):697–704.
   PubMed Web of Science ®Google Scholar
• Caetano MS, Zhang H, Cumpian AM, et al. IL6 blockade reprograms the lung tumor microenvironment to limit the development and progression of K-ras-mutant lung cancer. Cancer Res. 2016;76(11):3189–3199.
   PubMed Web of Science ®Google Scholar
• Otsuka S, Bebb G. The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer. J Thorac Oncol. 2008;3(12):1379–1383.
   PubMed Web of Science ®Google Scholar
• Tauler J, Mulshine JL. Lung cancer and inflammation: interaction of chemokines and hnRNPs. Curr Opin Pharmacol. 2009;9(4):384–388.
   PubMed Web of Science ®Google Scholar
• Pan H, Luo C, Li R, et al. Cyclophilin A is required for CXCR4-mediated nuclear export of heterogeneous nuclear ribonucleoprotein A2, activation and nuclear translocation of ERK1/2, and chemotactic cell migration. J Biol Chem. 2008;283:623–637.
   PubMed Web of Science ®Google Scholar
• Sueoka E, Sueoka N, Iwanaga K, et al. Detection of plasma hnRNP B1 mRNA, a new cancer biomarker, in lung cancer patients by quantitative real-time polymerase chain reaction. Lung Cancer. 2005;48(1):77–83.
   PubMed Web of Science ®Google Scholar
• Kuźnar-Kamińska B, Mikuła-Pietrasik J, Sosińska P, et al. COPD promotes migration of A549 lung cancer cells: the role of chemokine CCL21. Int J Chron Obstruct Pulmon Dis. 2016;11:1061–1066.
   PubMed Web of Science ®Google Scholar
• Shaykhiev R, Sackrowitz R, Fukui T, et al. Smoking-induced CXCL14 expression in the human airway epithelium links chronic obstructive pulmonary disease to lung cancer. Am J Respir Cell Mol Biol. 2013;49(3):418–425.
   PubMed Web of Science ®Google Scholar
• Ruan D, So SP. Prostaglandin E2 produced by inducible COX-2 and mPGES-1 promoting cancer cell proliferation in vitro and in vivo. Life Sci. 2014;116(1):43–50.
   PubMed Web of Science ®Google Scholar
• Chen Y, Chen P, Hanaoka M, et al. Enhanced levels of prostaglandin E2 and matrix metalloproteinase-2 correlate with the severity of airflow limitation in stable COPD. Respirology. 2008;13(7):1014–1021.
   PubMed Web of Science ®Google Scholar
• Xaubet A, Roca-Ferrer J, Pujols L, et al. Cyclooxygenase-2 is up-regulated in lung parenchyma of chronic obstructive pulmonary disease and down-regulated in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21(1):35–42.
   PubMed Web of Science ®Google Scholar
• Harris RE, Beebe-Donk J, Doss H, et al. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep. 2005;13(4):559–583.
   PubMed Web of Science ®Google Scholar
• Campa D, Zienolddiny S, Maggini V, et al. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis. 2004;25(2):229–235.
   PubMed Web of Science ®Google Scholar
• Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harbor Perspect Biol. 2009;1(5):a000141.
   PubMed Web of Science ®Google Scholar
• Caramori G, Adcock IM, Ito K. Anti-inflammatory inhibitors of IkappaB kinase in asthma and COPD. Curr Opin Invest Drugs. 2004;5(11):1141–1147.
   PubMedGoogle Scholar
• Sekine Y, Hata A, Koh E, et al. Lung carcinogenesis from chronic obstructive pulmonary disease: characteristics of lung cancer from COPD and contribution of signal transducers and lung stem cells in the inflammatory microenvironment. Gen Thorac Cardiovasc Surg. 2014;62(7):415–421.
   PubMedGoogle Scholar
• Greten FR, Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 2004;206(2):193–199.
   PubMed Web of Science ®Google Scholar
• Zaynagetdinov R, Sherrill TP, Gleaves LA, et al. Chronic NF-κB activation links COPD and lung cancer through generation of an immunosuppressive microenvironment in the lungs. Oncotarget. 2016;7(5):5470–5482.
   PubMedGoogle Scholar
• Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18(5):309–324.
   PubMed Web of Science ®Google Scholar
• Rajendrasozhan S, Yang SR, Edirisinghe I, et al. Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. Antioxid Redox Signal. 2008;10(4):799–811.
   PubMed Web of Science ®Google Scholar
• Belvisi MG, Mitchell JA. Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. Br J Pharmacol. 2009;158(4):994–1003.
   PubMed Web of Science ®Google Scholar
• Xue J, Schmidt SV, Sander J, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 2014;40(2):274–288.
   PubMed Web of Science ®Google Scholar
• Bhat TA, Panzica L, Kalathil SG, et al. Immune dysfunction in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2015;12(suppl 2):S169–S175.
   PubMedGoogle Scholar
• Virk H, Arthur G, Bradding P. Mast cells and their activation in lung disease. Transl Res. 2016;174:60–76.
   PubMed Web of Science ®Google Scholar
• Rijavec M, Volarevic S, Osolnik K, et al. Natural killer T cells in pulmonary disorders. Respir Med. 2011;105(suppl 1):S20–S25.
   PubMedGoogle Scholar
• Bozinovski S, Vlahos R, Anthony D, et al. COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link. Br J Pharmacol. 2016;173(4):635–648.
   PubMed Web of Science ®Google Scholar
• Guillon A, Jouan Y, Brea D, et al. Neutrophil proteases alter the interleukin-22-receptor-dependent lung antimicrobial defence. Eur Respir J. 2015;46(3):771–782.
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Caramori G, Gnemmi I, et al. T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. Clin Exp Immunol. 2009;157(2):316–324.
   PubMed Web of Science ®Google Scholar
• Tran HB, Jersmann H, Truong TT, et al. Disrupted epithelial/macrophage crosstalk via Spinster homologue 2-mediated S1P signaling may drive defective macrophage phagocytic function in COPD. PLoS One. 2017;12(11):e0179577.
   PubMed Web of Science ®Google Scholar
• Dehle FC, Mukaro VR, Jurisevic C, et al. Defective lung macrophage function in lung cancer ± chronic obstructive pulmonary disease (COPD/emphysema)-mediated by cancer cell production of PGE2? PLoS One. 2013;8(4):e61573.
   PubMed Web of Science ®Google Scholar
• Hodge S, Tran HB, Hamon R, et al. Nonantibiotic macrolides restore airway macrophage phagocytic function with potential anti-inflammatory effects in chronic lung diseases. Am J Physiol Lung Cell Mol Physiol. 2017;312(5):L678–L687.
   PubMed Web of Science ®Google Scholar
• Hopkins RJ, Young RP. Mevalonate signaling, COPD and cancer: the statins and beyond. J Investig Med. 2019;67(4):711–714.
   PubMed Web of Science ®Google Scholar
• Wiegman CH, Michaeloudes C, Haji G, et al. Oxidative stress-induced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2015;136(3):769–780.
   PubMed Web of Science ®Google Scholar
• Moon SH, Huang CH, Houlihan SL, et al. p53 represses the mevalonate pathway to mediate tumor suppression. Cell. 2019;176(3):564–580.
   PubMed Web of Science ®Google Scholar
• Kirkham PA, Caramori G, Casolari P, et al. Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;184(7):796–802.
   PubMed Web of Science ®Google Scholar
• Polverino F, Laucho-Contreras M, Quintero JR, et al. Increased expression of A Proliferation-inducing Ligand (APRIL) in lung leukocytes and alveolar epithelial cells in COPD patients with non small cell lung cancer: a possible link between COPD and lung cancer? Multidiscip Respir Med. 2016;11:17.
   PubMed Web of Science ®Google Scholar
• Beane J, Spira A, Lenburg ME. Clinical impact of high-throughput gene expression studies in lung cancer. J Thorac Oncol. 2009;4(1):109–118.
   PubMed Web of Science ®Google Scholar
• Devarakonda S, Masood A, Govindan R. Next-generation sequencing of lung cancers: lessons learned and future directions. Hematol Oncol Clin North Am. 2017;31(1):1–12.
   PubMed Web of Science ®Google Scholar
• Spira A, Beane JE, Shah V, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med. 2007;13(3):361–366.
   PubMed Web of Science ®Google Scholar
• Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010;463(7278):191–196.
   PubMed Web of Science ®Google Scholar
• Pleasance ED, Stephens PJ, O’Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2010;463(7278):184–190.
   PubMed Web of Science ®Google Scholar
• Goto Y, Shinjo K, Kondo Y, et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res. 2009;69(23):9073–9082.
   PubMed Web of Science ®Google Scholar
• Landi MT, Zhao Y, Rotunno M, et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res. 2010;16(2):430–441.
   PubMed Web of Science ®Google Scholar
• Obeidat M, Nie Y, Fishbane N, et al. Integrative genomics of emphysema-associated genes reveals potential disease biomarkers. Am J Respir Cell Mol Biol. 2017;57(4):411–418.
   PubMed Web of Science ®Google Scholar
• Keller A, Fehlmann T, Ludwig N, et al. Genome-wide microRNA expression profiles in COPD: early predictors for cancer development. Genomics Proteomics Bioinformatics. 2018;16(3):162–171.
   PubMed Web of Science ®Google Scholar
• Wang G, Wang R, Strulovici-Barel Y, et al. Persistence of smoking-induced dysregulation of miRNA expression in the small airway epithelium despite smoking cessation. PLoS One. 2015;10(4):e0120824.
   PubMed Web of Science ®Google Scholar
• Szabo M, Hajba L, Kun R, et al. Proteomic and glycomic markers to differentiate lung adenocarcinoma from copd. Curr Med Chem. 2018. [ Epub ahead of print]. DOI: 10.2174/0929867325666181017112939
   PubMedGoogle Scholar
• Dragonieri S, Pennazza G, Carratu P, et al. Electronic nose technology in respiratory diseases. Lung. 2017;195(2):157–165.
   PubMed Web of Science ®Google Scholar
• Deja S, Porebska I, Kowal A, et al. Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease. J Pharm Biomed Anal. 2014;100:369–380.
   PubMed Web of Science ®Google Scholar
• Jamal-Hanjani M, Wilson GA, McGranahan N, et al. TRACERx consortium. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017;376(22):2109–2121.
   PubMed Web of Science ®Google Scholar
• Blakely CM, Watkins TBK, Wu W, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017;49(12):1693–1704.
   PubMed Web of Science ®Google Scholar
• Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–451.
   PubMed Web of Science ®Google Scholar
• D’Agostini F, Mastracci L, Izzotti A, et al. Modulation by phenethyl isothiocyanate and budesonide of molecular and histopathologic alterations induced by environmental cigarette smoke in mice. Cancer Prev Res (Phila). 2009;2(6):546–556.
   PubMed Web of Science ®Google Scholar
• Khan A, Agarwal R. Lung cancer chemoprevention with inhaled corticosteroids? Am J Respir Crit Care Med. 2007;176(11):1169.
   PubMed Web of Science ®Google Scholar
• van Den Berg RM, van Tinteren H, van Zandwijk N, et al. The influence of fluticasone inhalation on markers of carcinogenesis in bronchial epithelium. Am J Respir Crit Care Med. 2007;175(10):1061–1065.
   PubMed Web of Science ®Google Scholar
• Liu S, Kuo H, Lin M, et al. Inhaled corticosteroids have a protective effect against lung cancer in female patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study. Oncotarget. 2017;8(18):29711–29721.
   PubMedGoogle Scholar
• Jian ZH, Huang JY, Lin FCF, et al. The use of corticosteroids in patients with COPD or asthma does not decrease lung squamous cell carcinoma. BMC Pulm Med. 2015;15:154.
   PubMed Web of Science ®Google Scholar
• Lee YM, Kim SJ, Lee JH, et al. Inhaled corticosteroids in COPD and the risk of lung cancer. Int J Cancer. 2018;143(9):2311–2318.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. UPLIFT study investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554.
   PubMed Web of Science ®Google Scholar
• Maneechotesuwan K, Wongkajornsilp A, Adcock IM, et al. Simvastatin suppresses airway IL-17 and upregulates IL-10 in patients with stable COPD. Chest. 2015;148(5):1164–1176.
   PubMed Web of Science ®Google Scholar
• Liu JC, Yang TY, Hsu YP, et al. Statins dose-dependently exert a chemopreventive effect against lung cancer in COPD patients: a population-based cohort study. Oncotarget. 2016;7(37):59618–59629.
   PubMedGoogle Scholar
• Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology. 2009;17(2):55–67.
   PubMedGoogle Scholar
• Thomas M, Ponce-Aix S, Navarro A, et al. Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase 2 IMPULSE study. Ann Oncol. 2018;29(10):2076–2084.
   PubMed Web of Science ®Google Scholar
• Lin Y, Bai L, Chen W, et al. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets. 2010;14(1):45–55.
   PubMed Web of Science ®Google Scholar
• Roeten MSF, Cloos J, Jansen G. Positioning of proteasome inhibitors in therapy of solid malignancies. Cancer Chemother Pharmacol. 2018;81(2):227–243.
   PubMed Web of Science ®Google Scholar
• Donovan JM, Zimmer M, Offman E, et al. Novel NF-κB inhibitor, edasalonexent (CAT-1004), in development as a disease-modifying treatment for patients with Duchenne muscular dystrophy: phase 1 safety, pharmacokinetics, and pharmacodynamics in adult subjects. J Clin Pharmacol. 2017;57(5):627–639.
   PubMed Web of Science ®Google Scholar
• Kamholz SL. Wine, spirits and the lung: good, bad or indifferent? Trans Am Clin Climatol Assoc. 2006;117:129–145.
   PubMedGoogle Scholar
• Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet Respir Med. 2005;365(9479):1552–1560.
   Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-smallcell lung cancer. N Engl J Med. 2015;373:1627–1639.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non small-cell lung cancer. N Engl J Med. 2015;373:123–135.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodr´ıguez-Abreu D, Robinson AG, et al. KEYNOTE-024 investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–1833.
   PubMed Web of Science ®Google Scholar
• Mark NM, Kargl J, Busch SE, et al. Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non-small cell lung cancer. Am J Respir Crit Care Med. 2018;197(3):325–336.
   PubMed Web of Science ®Google Scholar
• Shin SH, Park HY, Im Y, et al. Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. Int J Cancer. 2019. [Epub ahead of print]. DOI:10.1002/ijc.32235.
   Web of Science ®Google Scholar